20 May '22
LONDON , May 20, 2022 /PRNewswire/ -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care diagnostics company, announced today that its rapid COVID-19 antigen assay, LumiraDx SARS-CoV-2 Ag Test has successfully received the Emergency Use Listing (EUL) by the World Health Organization (
19 May '22
Results in just 5 minutes from sample application, aids in fast clinical decision-making at point of care (POC), helping to inform treatment decisions and prevent the further spread of infection, while also increasing testing throughput Run on the multi-assay LumiraDx Platform, the Ultra Test's
11 May '22
Strong Growth in Instruments Delivered to Customers and Continued Innovation on our Platform LONDON , May 11, 2022 /PRNewswire/ -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, today announced financial and operational results for the first quarter
10 Mar '22
Positive Customer Experience Drives Market Adoption and Expands Use Cases for LumiraDx's Transformative Diagnostic Solutions LONDON , March 10, 2022 /PRNewswire/ --  LumiraDx Limited (Nasdaq:LMDX), a next-generation point of care (POC) diagnostics company, today announced financial and operational
01 Mar '22
LONDON , March 1, 2022 /PRNewswire/ -- LumiraDx Limited (Nasdaq: LMDX) announced today that it entered into privately negotiated subscription agreements with certain investors pursuant to which LumiraDx agreed to sell and the investors agreed to purchase from LumiraDx (the "notes offering") $56.5